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Staphylococcus aureus is an opportunistic pathogen that colonizes human hosts and
causes a wide variety of diseases. Two interacting regulatory systems called agr
(accessory gene regulator) and sar (staphylococcal accessory regulator) are involved
in the regulation of virulence factors. The aim of this study was to evaluate the effect
of vancomycin on hld and spa gene expression during the exponential and post-
exponential growth phases in multidrug-resistant (MDR) S. aureus.
Methods: Antibiotic susceptibility was evaluated by the standard microdilution method.
The phylogenetic profile was obtained by pulsed-field gel electrophoresis (PFGE).
Polymorphisms of agr and SCCmec (staphylococcal cassette chromosome mec) were
analyzed by multiplex polymerase chain reaction (PCR). The expression levels of hld
and spawere analyzed by reverse transcription-PCR. An enzyme-linked immunosorbent
assay (ELISA) was performed to detect protein A, and biofilm formation was analyzed
via crystal violet staining.
Results: In total, 60.60% (20/33) of S. aureus clinical isolates were MDR. Half (10/20)
of the MDR S. aureus isolates were distributed in subcluster 10, with >90% similarity
among them. In the isolates of this subcluster, a high prevalence (100%) for the agrII
and the cassette SCCmec II polymorphisms was found. Our data showed significant
increases in hld expression during the post-exponential phase in the presence and
absence of vancomycin. Significant increases in spa expression, protein A production
and biofilm formation were observed during the post-exponential phase when the MDR
S. aureus isolates were challenged with vancomycin.
Conclusion: The polymorphism agrII, which is associated with nosocomial isolates,
was the most prevalent polymorphism in MDR S. aureus. Additionally, under our study
conditions, vancomycin modified hld and spa expression in these clinical isolates.
Therefore, vancomycin may regulate alternative systems that jointly participate in the
regulation of these virulence factors.
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Introduction
Staphylococcus aureus is an opportunistic pathogen capable of
causing a wide variety of diseases in humans, ranging from local-
ized infections of the skin and soft tissues to life-threatening
systemic infections (Archer, 1998; Shopsin and Kreiswirth, 2001;
David and Daum, 2010; Sowash and Uhlemann, 2014). An infec-
tion is initiated when S. aureus has access to subcutaneous
tissues and is disseminated by the circulatory system, and it
infects nearly every organ, leading to severe osteomyelitis, sepsis,
abscesses, endocarditis, pneumonia, and toxic shock syndrome
(Archer, 1998; Shopsin and Kreiswirth, 2001; David and Daum,
2010; Sowash and Uhlemann, 2014). S. aureus can produce a
remarkable array of wall surface and secreted virulence factors
that contribute to the establishment and maintenance of infec-
tion (Novick et al., 1993). These cell surface virulence factors
include microbial surface components that recognize extracel-
lular matrix proteins, such as ﬁbrinogen, laminin, plasminogen,
vitronectin, ﬁbronectin, thrombospondin, and bone sialoprotein
(Falord et al., 2011; Yamamoto et al., 2013). The secreted viru-
lence factors are generally produced during the post-exponential
or stationary phase, and they include several extracellular toxins
(i.e., alpha-, beta-, gamma-, and delta-hemolysin, enterotoxins,
exfoliative toxins A and B, and toxic shock syndrome toxin-1)
and exoenzymes (i.e., lipase, nucleases, proteases, hyaluronate
lyase, and metalloproteases; Chan and Foster, 1998; Kolar et al.,
2013).
The expression of virulence genes in S. aureus is regulated
under the partial control of the two-component quorum-sensing
system encoded by genes at the agr locus (Bronner et al., 2004).
The P2 transcript (RNAII) encodes the quorum-sensing system,
which consists of the following four proteins: AgrB (the secreted
protein responsible for the export and processing of AgrD to
its active form), AgrD (a signaling peptide), and AgrC-ArgA (a
two-component system in which AgrC is the transmembrane
receptor histidine kinase and AgrA is the DNA-binding response
regulator; Novick et al., 1995; Gilot et al., 2002; Novick, 2003;
Gilot and van Leeuwen, 2004). A high cell population density
causes the activation of AgrA, which induces the transcrip-
tion of the P3 promoter. Next, P3 drives the transcription of
RNAIII, a regulatory RNA that is both a positive and nega-
tive regulator of virulence factor production. The activation of
RNAIII transcription in response to an increase in cell popula-
tion density induces a transition in gene expression correlated
with metabolic changes and stress adaptations. Toxin- and extra-
cellular enzyme-encoding genes are positively regulated by the
agr-hld (δ-lysin gene) system, and the genes coding for protein
A (spa) and coagulase are negatively regulated (Morfeldt et al.,
1988). Protein A has a molecular weight of 42 kDa and is cova-
lently anchored to the peptidoglycan of S. aureus (Palmqvist
et al., 2002). Ninety percent of the molecule is localized in the
cell wall, and 10% is in the bacterial cytoplasm. Protein A is
an important virulence factor of S. aureus based on its abil-
ity to bind to a variety of ligands, including the Fc region of
IgG, the von Willebrand factor, tumor necrosis factor receptor-
1 (TNFR-1), the Fab-heavy chains of the Vh3 subclass, and the
epidermal growth factor receptor (EGFR; Cedergren et al., 1993;
Viau and Zouali, 2005; Gómez et al., 2006; O’Seaghdha et al.,
2006). An increase in protein A during the post-exponential
phase has been observed in agr-deleted S. aureus strains (Novick,
2003).
In addition, AgrA activation leads to increased transcription
of the δ-lysin gene (hld), which is located immediately upstream
of the agr operon (Janzon and Arvidson, 1990). δ-lysin is a small
polypeptide of only 26 amino acids. It is secreted without a signal
peptide, and it makes cation-selective channels in the phospho-
lipid bilayers (Lee and Birkbeck, 1984). δ-lysin is a virulence
factor with lytic activity in a wide range of cells, such as neu-
trophils, macrophages, mammalian erythrocytes, and bacterial
protoplasts, as well as in cellular organelles (Julander et al., 1983).
The aim of this study was to assess agr system expression by
quantifying hld and spa expression in multidrug-resistant (MDR)
S. aureus clinical isolates cultured from the exponential to post-
exponential growth phases in the presence of vancomycin. In
addition, the agr group I–IV polymorphisms were evaluated as
a factor that predisposes the permanence and survival of MDR
S. aureus clinical isolates during nosocomial or hospital-acquired
infections in the Hospital Infantil de México Federico Gómez
(HIMFG).
Materials and Methods
Bacterial Isolates
Thirty-three S. aureus from diﬀerent infections were obtained
from a clinical isolates collection at the Central Laboratory of the
HIMFG. The S. aureus isolates were collected from January 2006
to June 2007. They were cultured on 5% sheep blood agar plates
(Becton Dickinson, East Rutherford, NJ, USA) at 37◦C under 5%
CO2 for 24 h and kept at−70◦C in skim milk (Becton Dickinson,
East Rutherford, NJ, USA).
Diagnostic Tests for Identifying S. aureus
The bacteria were grown on blood agar, and identiﬁcation was
performed using conventional bacteriological techniques, such
as colony morphology examination, catalase assays, coagulase
assays, Gram staining (Sigma-Aldrich, St. Louis, MO, USA),
mannitol fermentation, and Brain Heart Infusion (BHI) broth
growth assays (Becton Dickinson, East Rutherford, NJ, USA)with
15% NaCl (MacFadin, 1996).
Antimicrobial Susceptibility
The antibiotic susceptibility proﬁles of the S. aureus isolates
were determined by the Minimum Inhibitory Concentration
(MIC) technique with the microdilution method in Mueller-
Hinton broth (MH; Becton Dickinson, East Rutherford, NJ,
USA), as recommended by the Clinical and Laboratory Standards
Institute (2014). TheMIC tests were conducted with vancomycin,
ciproﬂoxacin, erythromycin (MP Biomedicals, Solon, OH, USA),
clarithromycin (Grünenthal Gmbh, Aachen, Germany), oxacillin,
clindamycin, linezolid (Sigma-Aldrich, St. Louis, MO, USA),
meropenem (AstraZeneca Pharmaceuticals LP, Wilmington,
DE, USA), trimethoprim, sulfamethoxazole (Roche, Basel,
Switzerland), and gentamicin (Schering-Plough Pharmaceuticals,
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Kenilworth, NJ, USA). To identify methicillin-resistant S. aureus
clinical isolates, the bacteria were tested for oxacillin resis-
tance by the oxacillin-salt screening method. Oxacillin is a
more stable antibiotic than methicillin, although they are chem-
ically identical. S. aureus strain ATCC 29213 (American Type
Culture Collection, Manassas, VA, USA) was used as a positive
control.
Molecular Genotyping Assays
Pulsed-ﬁeld gel electrophoresis (PFGE) was performed using a
previously described protocol (Pereira et al., 2014). The chro-
mosomal DNA from MDR and sensitive S. aureus isolates was
digested with the Sma I restriction enzyme (Thermo Fisher
Scientiﬁc Inc., Life Technologies, Grand Island, NY, USA) and
subjected to electrophoresis on 1% agarose gels (Promega;
Madison, WI, USA) using the following parameters: 200 V
(6 v/cm) at 14◦C for 21.5 h, with an initial change of 5 s and
a ﬁnal change of 40 s. The gels were stained with 0.5 μg/mL
ethidium bromide solution (Sigma-Aldrich, St. Louis, MO, USA)
and visualized using a gel imaging system (ChemiDocTM MP
System, Biorad, Hercules, CA, USA). The DNA fragment pat-
terns generated by PFGE were analyzed with NTSY-pc soft-
ware (version 2.0, Applied Biostatistics, Inc., Port Jeﬀerson,
NY, USA; Ramazanzadeh et al., 2013) using the Sørensen–Dice
similarity coeﬃcient and the unweighted pair group method
with arithmetic mean (UPGMA) clustering approach (Dice,
1945).
Multiplex Polymerase Chain Reaction (PCR)
Conditions
The S. aureus clinical isolates were recovered from frozen stock
onto BHI agar plates and incubated at 37◦C for 18–24 h. Genomic
DNA extraction was performed with a Wizard Genomic DNA
Puriﬁcation Kit (Promega, Madison, WI, USA) from a bacterial
culture grown in BHI broth. Brieﬂy, the bacterial culture pellet
was mixed with TE buﬀer (10 mM Tris HCl and 1 mM EDTA,
pH 8.0), lysozyme (0.25 mg/mL; Sigma-Aldrich, St. Louis, MO,
USA), proteinase K (0.0125 mg/mL; Sigma-Aldrich, St. Louis,
MO, USA), and lysostaphin (0.062 mg/mL; Sigma-Aldrich, St.
Louis, MO, USA). Multiplex polymerase chain reaction (PCR)
assays for detecting agr polymorphisms (agrI, agrII, agrIII, and
agrIV; Table 1) were prepared according to the protocol for Go
Taq Green Master Mix (Promega, Madison, WI, USA). Multiplex
PCR reactions were prepared in a ﬁnal volume of 25 μL as
follows: 12.5 μL of Go Taq Green Master Mix 2x (Promega,
Madison, WI, USA), 2 μL of bacterial DNA (100 ng/μL), 5 μL
of agr primers (agrI, agrII, agrIII, and agrIV) at 10 pg/μL, and
5.5 μL of nuclease-free water. The DNA ampliﬁcation was per-
formed in a Veriti 96-Well Thermal Cycler-Life Technologies
(Applied Biosystems, Foster City, CA, USA) with the follow-
ing parameters: an initial denaturation at 94◦C for 5 min fol-
lowed by 26 ampliﬁcation cycles (denaturation at 94◦C for
30 s, annealing at 55◦C for 30 s, and extension at 72◦C for
60 s), ending with a ﬁnal extension at 72◦C for 7 min. An
external positive control [DNA extracted from S. aureus strains
USA300 (agrI), 1749 (agrII), and ATCC 25923 (agrIII)] and
an external negative control (DNase/RNase-free distilled water)
were included with each run. PCR amplicons (10 μL) were
loaded into a 1.5% (wt/v) agarose gel (Promega, Madison, WI,
USA) using a 100 bp DNA ladder (Promega, Madison, WI,
USA), and electrophoresis was performed in 1x TAE buﬀer at
100 V for 1 h. The bands were visualized using a gel imag-
ing system (ChemiDocTM MP System, Biorad, Hercules, CA,
USA).
The SCCmec genes (I, II, III, and IVa) were characterized by
multiplex PCR according to Cázares-Domínguez et al. (2015).
TABLE 1 | Primers used in agr and SCCmec typing by multiplex PCR.
Gene Primer Sequence (5′–3′) Amplicon size (bp) Reference
agrI agr I-F
agr I-R
ATGCACATGGTGCACATGC
GTCACAAGTACTATAAGCTGCGAT
441 Gilot et al. (2002)
agrII agr II-F
agr II-R
ATGCACATGGTGCACATGC
TATTACTAATTGAAAAGTGGCCATAGC
575 Gilot et al. (2002)
agrIII agr III-F
agr III-R
ATGCACATGGTGCACATGC
GTAATGTAATAGCTTGTAAAAAGTGGCCATAGC
323 Gilot et al. (2002)
agrIV agr IV-F
agr IV-R
ATGCACATGGTGCACATGC
CGATAATGCCGTAATACCCG
659 Gilot et al. (2002)
SCCmec I mec I-F
mec I-R
GCTTTAAAGAGTGTCGTTACAGG
GTTCTCTCATAGTATGACGTCC
613 Zhang et al. (2005)
SCCmec II mec II-F
mec II-R
CGTTGAAGATGATGAAGCG
CGAAATCAATGGTTAATGGACC
398 Zhang et al. (2005)
SCCmec III mec III-F
mec III-R
CCATATTGTGTACGATGCG
CCTTAGTTGTCGTAACAGATCG
280 Zhang et al. (2005)
SCCmec IVa mec IVa-F
mec IVa-R
GCCTTATTCGAAGAAACCG
CTACTCTTCTGAAAAGCGTCG
776 Zhang et al. (2005)
SCCmec V mec V-F
mec V-R
GAACATTGTTACTTAAATGAGCG
TGAAAGTTGTACCCTTGACACC
325 Zhang et al. (2005)
mecA mec 147-F
mec 147-R
GTGAAGATATACCAAGTGATT
ATGCGCTATAGATTGAAAGGAT
147 Zhang et al. (2005)
F, forward; R, reverse.
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RNA Extraction from S. aureus Clinical
Isolates
Staphylococcus aureus isolates that were grown overnight were
adjusted to an optical density of 0.05 at 600 nm and incu-
bated in BHI with 1 μg/mL vancomycin. The bacterial cul-
tures were grown for 4 h until reaching the exponential phase
(OD600 of 0.6–0.8) and for 11 h just in the post-exponential
phase (OD600 of 1.2–1.4). Aliquots of bacterial cultures were
harvested by centrifugation at 10,000 × g for 3 min at 4◦C.
Each pellet was washed in an equal volume of TE buﬀer
(10 mM Tris HCl and 1 mM EDTA, pH 8.0) three times and
lysed with the same buﬀer supplemented with 0.25 mg/mL
lysozyme, 0.0125 mg/mL proteinase K, and 0.062 mg/mL
lysostaphin. Total bacterial RNA was isolated (TRIzol, Life
Technologies, Carlsbad, CA, USA) according to the manufac-
turer’s directions. After puriﬁcation, contaminating DNA was
removed with RNase-free DNase I (2 U/10 μg of total bacte-
rial RNA at 37◦C for 30 min). The RNA was then re-puriﬁed
with RNeasy Minicolumns (Qiagen Incorporated, Ln Valencia,
CA, USA). The amount of recovered RNA was determined
spectrophotometrically, and the samples were then stored at
−80◦C.
Transcriptional Expression Analyses of the
spa and hld Genes
The relative expression levels of the spa and hld genes were deter-
mined by cDNA-PCR. The puriﬁed RNA of all S. aureus clinical
isolates was employed for reverse transcription (RT)-PCR assays
with the GeneAmp RNA PCR Kit (Applied Biosystems, Foster
City, CA, USA), using speciﬁc primers for the spa (encoding
protein A) and hld (encoding a delta toxin) genes (Table 2).
A GeneAmpRNA PCRKit was used with 0.2μg of total RNA per
reaction as a template for PCR ampliﬁcation. Reactions contain-
ing S. aureus cells alone, only RNA, or no reverse transcriptase
were used as negative controls. Speciﬁc primers were used for the
ampliﬁcation of 16S RNA, which was used as an internal control
(Table 2).
The expression levels of spa and hld transcripts from S.
aureus clinical isolates were quantiﬁed by densitometric analy-
sis with Bio-Rad image software (Bio-Rad chemi-doc, Quantity
one 4.4.1). The data are expressed as the mean ± stan-
dard error of the means. A p-value of less than 0.05 was
considered signiﬁcant. All experiments were repeated at least
three times, and a representative result is shown for each
experiment.
Quantitative Measurements of Protein A
A qualitative screening test for the production of protein A was
conducted by an enzyme linked immunosorbent assay (ELISA).
Brieﬂy, 96-well plates containing 200 μL of BHI were inoculated
with 10 μL (1.5 × 108 bacteria/mL) of bacterial suspensions and
incubated at 37◦C in the presence or absence of vancomycin to
the exponential phase (4 h) and post-exponential phase (11 h).
Cell wall-associated protein A was identiﬁed using anti-protein
A, followed by mouse anti-IgG antibodies, o-phenylenediamine
(OPD) compounds, and ELISA as previously described (Ohkaru
et al., 1995).
Quantitative Determination by Biofilm
Assays
Bioﬁlm formation was quantitatively analyzed according to the
protocol described by Erdem et al. (2008). MDR and sensitive
S. aureus clinical isolates were grown in BHI broth overnight at
37◦C. Then, 96-well plates containing 200 μL of BHI were inocu-
lated with 10 μL (1.5 × 108 bacteria/mL) of bacterial suspensions
and grown at 37◦C in the presence or absence of vancomycin in
the exponential phase (4 h) and post-exponential phase (11 h).
The bioﬁlms that developed on the surfaces of the wells were gen-
tly washed three times with 1x phosphate-buﬀered saline (PBS;
pH 7.4) and ﬁxed with 2% formaldehyde at 4◦C overnight. Wells
with ﬁxed bioﬁlms were decanted, washed three times with PBS
and stained with 200 μL of 1% crystal violet for 30 min. The
excess crystal violet was removed, and the plates were washed
twice with water. Crystal violet was subsequently solubilized in
70% methanol, and the absorbance was determined at 620 nm.
Assays were performed in triplicate and repeated three consecu-
tive times.
Results
The Antimicrobial Susceptibility Testing of
S. aureus Clinical Isolates
Thirty-three S. aureus clinical isolates were tested for antimicro-
bial susceptibility. In total, 60.60% (20/33) of S. aureus clinical
isolates were MDR, 100% (33/33) were sensitive to four antibi-
otics (vancomycin, trimethoprim/sulfamethoxazole, gentamicin,
and linezolid), and 39.39% (13/33) were sensitive to all antimi-
crobials (Table 3).
Molecular Typing Analysis of the MDR and
Sensitive S. aureus Isolates by PFGE
A total of 19 DNA pulsotypes grouped in four clusters (I–IV)
were identiﬁed, revealing patterns that consisted of 11–18 DNA
fragments ranging in size from 48.5 to 339.5 Kb (Figure 1). In
total, 3.03% (1/33) of the S. aureus clinical isolates were identiﬁed
as pulsotype F, and cluster I showed 38% genetic similarity when
compared with other pulsotypes. Four pulsotypes (E, I, K, and
M) belonging to cluster II included 21.21% (7/33) of the S. aureus
clinical isolates with 64% genetic similarity. In addition, the nine
pulsotypes (H, J, L, N, O, P, Q, R, and S) organized in cluster
III included 54.55% (18/33) of the S. aureus clinical isolates with
TABLE 2 | Primers used in hld and spa expression analysis by RT-PCR.
Gene Primer sequence (5′–3′) Product
size (bp)
Reference
spa TATCTGGTGGCGTAACACCTG
GATGAAGCCGTTACGTTGTTC
322 Goerke et al.
(2000)
hld GAAGGAGTGTTTCAATGG
TAAGAAAATACATAGCACTGAG
260
Goerke et al.
(2000)
16S TCCGGAATTATTGGGCGTAA
CCACTTTCCTCTTCTGCACTCA
121 Goerke et al.
(2000)
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TABLE 3 | MIC analysis for the MDR and sensitive S. aureus clinical isolates.
Clinical isolates Antibiotics (µg/mL)
CEC CEP VAN CLA CIP STX OXA GEN ERI MEM LZN
488H, 428H, 10H, 714H ≥128 ≥128 1 ≥128 64 0.5 16 1 ≥128 64 2
242H, 143H ≥128 ≥128 1 ≥128 ≥128 2 ≥128 0.5 ≥128 32 4
246H, 175H ≥128 ≥128 1 ≥128 ≥128 1 ≥128 0.5 ≥128 16 4
882HR ≥128 ≥128 1 ≥128 64 1 ≥128 1 ≥128 32 2
425LCR ≥128 ≥128 1 ≥128 64 0.5 16 0.5 ≥128 64 2
330H ≥128 ≥128 1 ≥128 ≥128 2 ≥128 1 ≥128 32 4
783H ≥128 ≥128 1 ≥128 ≥128 2 ≥128 1 ≥128 32 4
902H ≥128 ≥128 1 ≥128 64 1 ≥128 2 ≥128 32 4
54H ≥128 ≥128 0.5 ≥128 64 0.5 16 0.5 ≥128 32 2
A-32 ≥128 ≥128 0.5 ≥128 ≥128 0.5 ≥128 0.5 ≥128 16 2
828H 8 ≥128 1 ≥128 64 0.5 16 0.5 ≥128 64 2
931H 8 ≥128 1 ≥128 64 0.5 16 1 ≥128 64 2
260H 0.125 64 0.5 32 0.25 0.5 64 0.5 ≥128 8 0.5
622H 0.125 ≥128 1 0.06 0.25 1 32 0.5 0.25 4 4
299H 0.060 ≥128 1 ≥128 32 0,5 8 0.5 ≥128 0.12 0.5
679H, 318LCR, 573H, 770H, 633H,
779H, 291H, 336H, 18H, 108H, 780H,
493H, 198H
≤0.25 ≤8 ≤1 ≤0.25 ≤2 ≤1 ≤1 ≤1 ≤1 ≤0.125 ≤4
CVR∗ ≥32 ≥32 ≥16 ≥8 ≥4 ≥4 ≥4 ≥16 ≥8 ≥16 ≥8
CEC, cefaclor; CEP, cephalothin; VAN, vancomycin; CLA, clarithromycin; CIP, ciprofloxacin; STX, trimethoprim/sulfametoxazole; OXA, oxacillin; GEN, gentamicin; ERI,
erythromycin; MEM, meropenem; LZN, linezolid. The MDR S. aureus clinical isolates are marked in gray. ∗Cut-off values for resistance to MIC (µg/mL; CVR).
56% genetic similarity. In this cluster, the S. aureus clinical iso-
lates with >90% genetic similarity were grouped in subcluster 10
and distributed in the following order: two isolates in pulsotype
Q, one isolate in pulsotype R, and eight isolates in pulsotype J
(Figure 1). In addition, 21.21% (7/33) of the S. aureus clinical iso-
lates were classiﬁed as cluster IV with 62% genetic similarity and
distributed as pulsotypes A, B, C, D, and G (Figure 1).
Only one S. aureus clinical isolate sensitive to all antibiotics
was identiﬁed (pulsotype F of cluster I; Figure 1). Four MDR and
three sensitive S. aureus clinical isolates were distributed in the
four pulsotypes (E, I, K, and M) of cluster II (Figure 1). Fourteen
MDR and four sensitive S. aureus clinical isolates were distributed
into the nine pulsotypes (H, J, L, N, O, P, Q, R, and S) of cluster
III. Interestingly, seven MDR and one sensitive S. aureus clini-
cal isolates that were distributed in pulsotype J were organized in
subcluster 10. In addition, two MDR and ﬁve sensitive S. aureus
clinical isolates were distributed over the ﬁve pulsotypes (A, B, C,
D, and G) of cluster IV (Figure 1).
Distributing agr, SCCmec, hld, and spa
Genes by Multiplex PCR Endpoint Analysis
Multiplex PCR ampliﬁcation assays were performed for agr-
speciﬁc group identiﬁcation in the selected MDR and sensitive
S. aureus clinical isolates. Our results showed three diﬀerent
agr speciﬁcity groups (Figures 2A,B), which were identiﬁed
according to the expected product sizes (Table 1). Brieﬂy, the
sensitive S. aureus clinical isolates were 30.76% (4/13) agrI,
30.76% (4/13) agrII, and 38.46% (5/13) agrIII (Figures 2B,C).
The MDR S. aureus clinical isolates were 70% (14/20) agrII, 10%
(2/20) agrI, and 10% (2/20) agrIII (Figures 2A,C). Furthermore,
both the agrI/II and agrII/III polymorphism groups were iden-
tiﬁed in a single (1/20; 5%) clinical isolate of MDR S. aureus
(Figures 2A,C). The expression of the agrIV was not iden-
tiﬁed in either the MDR or sensitive S. aureus clinical iso-
lates.
A 398 bp product corresponding to the SCCmec group II
polymorphism was present in 60.60% (20/33) of the MDR S.
aureus clinical isolates that were distributed in the fourth clus-
ter as determined by PFGE. A SCCmec II polymorphism was
observed in 12.12% (4/33) of the isolates in cluster II, 42.42%
(14/33) of the isolates in cluster III, and 6.06% (2/33) of the iso-
lates in cluster IV. However, the SCCmec II polymorphism was
not identiﬁed in cluster I (Figure 1). Moreover, SCCmec poly-
morphism types I, III, and IV were not identiﬁed in the MDR
S. aureus clinical isolates (Figure 1). It is important to empha-
size that the presence of the SCCmec gene explains methicillin
(oxacillin) resistance; therefore, it was not identiﬁed in sensitive
S. aureus clinical isolates (Figure 1).
The frequencies of the hld and spa genes were determined
using speciﬁc primers to be 100% (33/33) in MDR and sensitive
S. aureus clinical isolates. Our results showed two bands, which
corresponded to hld at 260 bp and spa at 322 bp (data not shown).
hld and spa Gene Expression as Determined
by RT-PCR
The speciﬁc transcripts of the spa and hld genes produced by
the ten MDR S. aureus isolates that were distributed in subclus-
ter 10 of cluster III were quantiﬁed by RT-PCR-densitometry.
These MDR S. aureus isolates were treated with and without
vancomycin during two diﬀerent stages of the growth phase
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FIGURE 1 | Dendrogram analysis of PFGE results showing the genetic
relationships among the PFGE profiles and the presence of agr and
SCCmec type among the 33 S. aureus clinical isolates. A phylogenetic
analysis was conducted using the Sørensen–Dice similarity coefficient in
association with the UPGMA algorithm as the grouping method. The
dendrogram was evaluated by obtaining the cophenetic correlation coefficient
with the Mantel test, which yielded an r-value of 0.9077. Antimicrobial
susceptibility profile (ASP), multidrug-resistant (MDR), sensitive (S). The dotted
line indicates that the clinical isolates that belong to subcluster 10 with >90%
genetic similarity.
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FIGURE 2 | Multiplex PCR assays for identifying agr types. (A) MDR
S. aureus clinical isolates showing the agrI (441 bp), agrII (575 bp), and agrIII
(323 bp) types. (B) Sensitive S. aureus clinical isolates. (C) The percentages of
agr types that were identified in MDR and sensible S. aureus clinical isolates. S.
aureus strain USA300 (agrI), 1749 (agrII), and ATCC 25923 (agrIII) were used as
reference strains. MW, molecular weight (bp).
(exponential and post-exponential). The hld expression in MDR
S. aureus clinical isolates showed a signiﬁcant increase (1.68-fold;
p = 0.0001) when cultured from the exponential to the post-
exponential growth phase in the absence of vancomycin as well
as a signiﬁcant increase (2.04-fold; p = 0.0001) when grown in
the presence of vancomycin (Figure 3A). Interestingly, under the
same test conditions, a signiﬁcant increase (2.07-fold; p= 0.0001)
in hld expression was observed in MDR S. aureus clinical iso-
lates in the exponential growth phase treated with vancomycin
compared to those treated without vancomycin (Figure 3A). In
addition, a signiﬁcant increase (2.53-fold; p = 0.0001) in hld
expression was observed in the MDR S. aureus clinical isolates
cultured to the post-exponential growth phase when challenged
with 1 μg/mL vancomycin compared to without vancomycin
challenge (Figure 3A). The hld expression in sensitive S. aureus
isolates showed increases from the exponential to the post-
exponential growth phase in both the presence and absence of
vancomycin (data not shown).
The spa expression level showed a signiﬁcant reduction (4.01-
fold; p = 0.0001) when the MDR S. aureus clinical isolates
were cultured from the exponential to post-exponential growth
phases in the absence of vancomycin (Figure 3B). Interestingly,
a remarkable increase (3.67-fold; p = 0.0001) in spa expres-
sion was observed from the exponential to the post-exponential
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FIGURE 3 | Expression levels of the hld and spa genes determined by
RT-PCR in MDR S. aureus clinical isolates cultured from the
exponential to post-exponential growth phases in the presence of
vancomycin. (A) hld expression; (B) spa expression. The densitometric
results of the transcripts were quantified using the Quantity One program and
analyzed by paired Student’s t-tests. E, exponential; PE, post-exponential.
phases in MDR S. aureus clinical isolates cultured in the pres-
ence of vancomycin (Figure 3B). During the exponential phase,
a signiﬁcant reduction in spa expression (2.42-fold; p = 0.0001)
was observed when the MDR S. aureus clinical isolates were
challenged with vancomycin compared to those grown in the
absence of vancomycin; the MDR S. aureus clinical isolates in
the post-exponential growth phase showed a signiﬁcant increase
(4.10-fold; p = 0.0001) in spa expression when challenged with
vancomycin compared to those grown in the absence of van-
comycin (Figure 3B). The spa expression level did not show a
signiﬁcant changes (reduction and/or increase) when the sensi-
tive S. aureus clinical isolates were cultured in the exponential
and post-exponential growth phases in the presence or absence
of vancomycin (data not shown).
Protein A Immunodetection by ELISA
Protein A immunodetection assays were performed for the
MDR S. aureus clinical isolates distributed in subcluster 10 of
cluster III. Quantitative analysis showed a signiﬁcant reduc-
tion (2.39-fold; p = 0.0001) in protein A expression in the
FIGURE 4 | Protein A production in the MDR S. aureus clinical isolates
cultured from the exponential to post-exponential growth phases in
the presence of vancomycin. A significant reduction of 2.39-fold
(p = 0.0001) was observed in the MDR S. aureus clinical isolates when they
were cultured from the exponential to post-exponential growth phases in the
absence of vancomycin and there was a significant increase of 1.38-fold
(p = 0.0001) when cultured from the exponential to post-exponential growth
phase when challenged with 1 μg/mL vancomycin.
post-exponential phase compared to the exponential phase in
the absence of vancomycin (Figure 4). Furthermore, a signif-
icant increase (1.38-fold; p = 0.0001) in protein A expres-
sion was observed from the exponential to the post-exponential
growth phase in the MDR S. aureus clinical isolates cultured
the presence of 1 μg/mL vancomycin. Interestingly, a signiﬁ-
cant increase (4.10-fold; p = 0.0001) in protein A expression
was observed in these clinical isolates cultured to the post-
exponential growth phase in the presence of vancomycin com-
pared to in the absence of vancomycin (Figure 4). Likewise,
a signiﬁcant increase (1.23-fold; p = 0.0001) in protein A
expression was observed in the MDR S. aureus clinical iso-
lates that were cultured to the exponential growth phase in the
presence of vancomycin compared to in the absence of van-
comycin.
Clinical Strains of MDR and Sensitive
S. aureus Isolates Produce Biofilms
A crystal-violet bioﬁlm assay was performed for the MDR
S. aureus clinical isolates that were distributed in subcluster 10 of
cluster III. Quantitative analysis showed no diﬀerence in bioﬁlm
formation when the MDR S. aureus clinical isolates were cul-
tured to the exponential and post-exponential growth phases in
the absence of vancomycin. In the presence of vancomycin, a
signiﬁcant increase (1.42-fold; p = 0.0001) was observed in the
bioﬁlm formation of the MDR S. aureus clinical isolates cul-
tured to the exponential growth phase and a signiﬁcant increase
(1.85-fold; p = 0.0001) was observed in the isolates cultured
to the post-exponential growth phase. Furthermore, a signif-
icant increase (1.35-fold; p = 0.0001) in the bioﬁlm forma-
tion of these isolates was observed from the exponential to
Frontiers in Microbiology | www.frontiersin.org 8 May 2015 | Volume 6 | Article 369
Cázares-Domínguez et al. Vancomycin modifies agr expression
FIGURE 5 | Biofilm assays of the MDR S. aureus clinical isolates when
cultured from the exponential to post-exponential growth phases in
the presence of vancomycin. Interestingly, a significant increase (1.35-fold;
p = 0.0001) in biofilm formation was observed in the MDR S. aureus clinical
isolates cultured from the exponential to post-exponential growth phases in
the presence of the vancomycin.
post-exponential growth phases in the presence of vancomycin
(Figure 5).
Discussion
In this study, 100% of S. aureus clinical isolates showed sensitive
to vancomycin, trimethoprim/sulfamethoxazole, gentamicin, and
linezolid. Low rates of resistance to tetracycline, gentamicin, and
trimethoprim/sulfamethoxazole in clinical methicillin-resistant
staphylococcus aureus (MRSA) isolates have been described in
other studies (Bordon et al., 2010; Davis et al., 2013). However,
the impressive ability of S. aureus to develop resistance against
various antibiotics through point mutations, transposons, plas-
mids, and resistance cassettes is the most likely reason for the
rapid increase in antimicrobial resistance worldwide in recent
years (Sakoulas and Moellering, 2008). High levels of ery-
thromycin resistance and increasing ciproﬂoxacin resistance in
MRSA clinical isolates have been observed (Davis et al., 2013).
The clinical condition, the administration route, and the resis-
tance pattern of the organism are also risk factors that are
considered in treating MRSA infections when drugs such as van-
comycin, linezolid, daptomycin, clindamycin, and mupirocin are
administered (Liu et al., 2011). The increase of vancomycin-
resistant S. aureus (VRSA) isolates in the United States could be
explained by the selective pressure originating from the excessive
use of vancomycin to treat MRSA infections (David and Daum,
2010). The high frequency of resistance to the antibiotics tested
in our study may reﬂect the fact that the public health service
in Mexico prescribes all of these antibiotics for treating pediatric
patients; these drugs are considered to be essential in this health
sector.
According to the PFGE analysis, 33.33% (11/33) of the S.
aureus clinical isolates distributed in subcluster 10 shared 90%
similarity. In particular, 50% of the MDR S. aureus clinical
isolates were distributed in subcluster 10 and showed closely
related pulsotypes with three clones that were assigned as J, Q,
and R according to the criteria of Tenover et al. (1995). These
results suggest that MDR S. aureus isolates are associated with
patients with infections acquired during their current hospi-
tal stay. MRSA isolates with a highly related PFGE type have
been associated with an MDR proﬁle to β-lactams, gentamicin,
ciproﬂoxacin, clindamycin, and erythromycin (Velazquez-Meza
et al., 2004). In total, 90.90% (10/11) of the S. aureus clinical iso-
lates belonging to subcluster 10 were resistant to six antibiotics,
namely cephalothin, clarithromycin, ciproﬂoxacin, oxacillin, ery-
thromycin, andmeropenem. Furthermore, 72.72% (8/11) of these
clinical isolates were resistant to cefaclor.
Our data showed a high prevalence of the agr group II
polymorphism, with a PCR-ampliﬁed product of 575 kb, in the
MDR S. aureus clinical isolates belonging to subcluster 10 by
PFGE analysis. Several studies performed in Japan and the USA
described the agr group II polymorphism as the agr type that
was most frequent in MDR S. aureus clinical isolates, and it
has been associated with nosocomial infections from pediatric
patients (Sakoulas et al., 2003). Similar ﬁndings indicated that
all S. aureus clinical isolates from diverse geographic origins and
those recovered from patients undergoing intubation showed the
agr group II polymorphism (Sakoulas et al., 2002; Goerke et al.,
2003; Moise et al., 2004). Furthermore, the agr group II poly-
morphism in MRSA predicts the failure of vancomycin therapy
(Moise et al., 2007).
We further evaluated agr expression through indirect
mechanisms by quantiﬁcation of hld and spa expression in
MDR S. aureus clinical isolates during the exponential and post-
exponential growth phases and upon vancomycin challenge.
Our RT-PCR analysis showed that hld activation occurs during
the post-exponential growth phase, resulting in an increase of
1.68-fold without vancomycin and 2.04-fold with vancomycin
compared with the exponential phase. The increased hld
expression in the MDR S. aureus clinical isolates of subcluster
10 suggested that the activation of this gene is inﬂuenced
by the growth phase and vancomycin challenge. Other stud-
ies have shown signiﬁcant increases in hld expression at the
end of the exponential growth phase by an agr-dependent
mechanism that is involved in the regulation of virulence
genes. agrA codes for a protein that can activate hld tran-
scription as a response to the growth phase (Janzon and
Arvidson, 1990). Our data indicated that the MDR S. aureus
isolates were stimulated by vancomycin at subinhibitory con-
centrations, as indicated by increases in hld expression. These
results indicate that the antibiotic stimulates the agr system.
In a previous study, the over-expression of the hld transcript
in vancomycin-resistant S. aureus strains associated with acti-
vation of the sigma factor was observed when these isolates
were exposed to subinhibitory antibiotic concentrations (Chen
et al., 2011). Recently, community-associated (CA) MRSA was
challenged with subinhibitory concentrations of tetracycline and
clindamycin, which had a strong stimulatory eﬀect on the activity
of the agr operon (Joo et al., 2010). These results, together with
the data obtained in our studies, suggest that vancomycin also
exerts a strong stimulatory eﬀect on the activity of the agr operon.
It is important to note that agr controls many virulence factors of
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S. aureus and that vancomycin is frequently used in Mexico for
treating MRSA infections in pediatric patients.
Interestingly, a reduction in spa expression was observed dur-
ing the exponential to post-exponential growth phases when
MDR S. aureus clinical isolates were cultured without van-
comycin. In contrast, a signiﬁcant increase (3.67-fold) in spa
expression was observed when MDR S. aureus clinical isolates
were only cultured with vancomycin during the post-exponential
growth phase. These data suggest that spa activation or repres-
sion is regulated by the growth phase and that expression of spa
mRNA is modiﬁed by drugs such as vancomycin. In previous
studies, CA-MRSA isolates treated with daptomycin and van-
comycin showed no change in spamRNA and SpA protein levels
(Subrt et al., 2011; Otto et al., 2013). However, in a diﬀerent study,
the expression levels of diﬀerent virulence factors in the CA-
MRSA isolates were suppressed in the presence of clindamycin
and linezolid (Otto et al., 2013).
The expression levels of the spa gene are directly correlated
with protein A production because most of the gene transcript
is translated as protein A. The localization of protein A in the
cell wall could contribute to bioﬁlm formation in MRSA clinical
isolates during the post-exponential phase and when challenged
with vancomycin. The XdrA regulator has almost as strong an
activating eﬀect on spa as SarS, and it acts on the same spa oper-
ator regions (identiﬁed potential cis-acting regulatory regions) as
SarS or on closely overlapping regions (McCallum et al., 2010).
The current evidence suggests that XdrA directly regulates spa
transcripts independently of other well-characterized regulators.
The over-expression of spa transcripts and protein A in the MDR
S. aureus clinical isolates challenged with vancomycin could also
be related to the action of the regulator XdrA, which should be
examined in future studies. In addition, the variation in the levels
of spa transcripts during diﬀerent growth phases is likely due to
the inﬂuence of other regulators and/or to the characteristics of
clinical isolates.
Conclusion
Staphylococcus aureus clinical strains are inﬂuenced by inter-
cellular signaling through the agr system, which modulates the
activation and/or repression of many outer membrane proteins
associated with bioﬁlms (Caﬁso et al., 2012). Vancomycin is the
antibiotic of choice for treating nosocomial infections of MDR S.
aureus clinical isolates in pediatric patients at the HIMFG. These
data provide a direct evidence for evaluating the role of virulence
genes (hld and spa) associated with agr regulation and suggest the
participation of other regulatory elements; which are include an
operon that activates many virulence factors that could be impor-
tant during infection by this nosocomial pathogen. In our study,
the polymorphism agrII was associated with nosocomial isolates
and was the most prevalent polymorphism in MDR S. aureus.
Our ﬁnding showed that vancomycin modiﬁed the hld and spa
expression in the MDR S. aureus clinical isolates; suggesting that,
vancomycin may regulate alternative systems that jointly partic-
ipate in the regulation of virulence factors involved in bacteria
pathogenesis, which allows spread and adaptation into a hospital
environmental.
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